Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

Also called NCT01768702

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 315 participants (enrolled count) (from the registry)
Sponsor
Celyad Oncology SA (from the registry)
Registry
  • NCT NCT01768702
  • EudraCT 2011-001117-13
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Bulgaria, Hungary, Israel, Italy, Poland, Serbia, Spain, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01768702. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2017-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
Acronym
CHART-1
Condition
Heart Failure
Intervention (Biological)
Injection of C3BS-CQR-1
Intervention (Biological)
Sham, no injection
Lead sponsor
Celyad Oncology SA (class: industry)

Record details

Record id
cardio:ct-nct01768702
Content hash
2db75604de63a5d08b640e9fa08a2177242d279bd5a7b8f2d31b3e2cd4a23017